Introduction
The obtention of retroviral vectors that are suitable for an in vivo gene delivery has been a recurrent theme in gene therapy research over the last decade. Substantial progress has been achieved towards this goal: (1) human complement-resistant retroviral vectors can now be generated thanks to the development of human cell-derived packaging cell lines 1, 2 and to the use of specific retroviral envelope glycoproteins; 1, 3 (2) methods that optimize the production and quality of retroviral vectors have been developed; 4,5 (3) several strategies aimed at targeting gene delivery and/or expression have been described; [6] [7] [8] and (4) new vectors that allow gene delivery into nonproliferating cells have now emerged. 9, 10 Retroviral vectors derived from murine leukemia viruses (MLVs) and from other type C and D mammalian retroviruses have proved to be extremely useful and adaptable in transducing target cells cultivated in vitro or ex vivo. Although they may be used in vivo in situations gene transfer, expression of the GFP in the target cells remained constant after several weeks, indicating that the vectors had been stably integrated into the genome of the host cells. Preparations of SIV vectors were systematically checked for the absence of replication-competent and recombinant retroviruses but remained negative, suggesting the innocuousness of these novel gene delivery vectors. Side-to-side comparisons with vectors derived from HIV-1 (human immunodeficiency virus) indicated that the SIV vectors were equally potent in transducing proliferating target cells. Finally, we have determined the infectivity of SIV vectors pseudotyped with surface glycoproteins of several membrane-enveloped viruses. Gene Therapy (2000) 7, 1613-1623. where the target tissue is proliferating 11 or under regeneration, 12 the most important limitation of MLV-derived vectors is their inability to allow transgene integration into nondividing or slowly proliferating target cells. [13] [14] [15] The requirements by target cells to undergo mitosis to be successfully transduced by MLV-based vectors are not clear although it is currently assumed that the MLV preintegration complex (PIC) , that is formed with the retroviral genome and some viral core proteins after virion penetration and uncoating, cannot be transported through the nuclear pore and must await the nuclear membrane breakdown that accompanies mitosis to gain access into the host chromatin. 14, 16 In contrast to MLVs, lentiviruses are able to infect post-mitotic cells. 17, 18 The reasons for this major difference are still unclear but seem to rely on the ability of the PIC of lentiviruses to be transported across the nuclear membrane. 19 Several karyophilic determinants in the lentiviral PIC may interact with the nuclear import machinery [20] [21] [22] and may allow PIC translocation into the nucleus. 23 Possible strategies to obtain MLV-derived retroviral vectors capable of infecting nondividing cells may therefore consist in the substitution of MLV proteins by the corresponding HIV proteins that permit interaction with the nuclear import machinery 24 or in the introduction of NLS sequences into MLV PIC proteins. As an alternative and more effective strategy, several groups have reported the generation of retroviral vectors derived from lentiviruses such as HIV-1, 25, 26 HIV-2, 27 SIV, 28, 29 feline immunodeficiency virus, 30 or equine infectious anemia virus. 31, 32 The development of lentivirus-based vectors, particularly those derived from HIV-1, is a rapidly progressing field and several studies have demonstrated that these vectors can transduce nondividing cells ex vivo 15, 26, 33, 34 and in vivo. 25, [35] [36] [37] [38] [39] Despite all the safeguards that have progressively been introduced in lentiviral vectors, the clinical acceptance of vectors derived from pathogenic lentiviruses is still a subject of debate. It is therefore essential to design vectors derived from a wide range of lentivirus types and to examine comparatively their properties in terms of transduction efficiency and biosafety. Here, we report the characterization of lentivirus vectors derived from SIVmac251, a nonpathogenic molecular clone of simian immunodeficiency virus that can efficiently replicate in primate cells. 40 We have examined the performance of several SIV vector packaging constructs that are equivalent to the first, 25 second 41 and third 42, 43 generations of HIV-1-based vectors. The lentivirus vectors were produced following transient expression of plasmid DNAs encoding the transfer vector and the packaging functions in 293 human cells. Both HIV-1-based and SIV derived lentiviral vectors were similar in their capacity to transduce proliferating target cells in side-to-side experiments. We also report here the characterization of SIV vectors pseudotyped with glycoproteins from various membrane-enveloped viruses that include VSV (vesicular stomatitis virus), MLV (murine leukemia virus), GALV (gibbon ape leukemia virus) and influenza virus. Finally, we show here that monocyte-derived, nonproliferating, mature human dendritic cells could be efficiently transduced at low multiplicity of infection with the novel lentivirus vectors.
Results
Functional evaluation of SIV-derived packaging constructs A series of expression plasmids encoding the viral core packaging functions of SIVmac251, an infectious molecular clone of simian immunodeficiency virus (SIV), was generated ( Figure 1a ). Our strategy was progressively to eliminate all the SIV sequences unnecessary for formation of vector particles. Starting from a raw packaging construct (pSIV2 construct), from which only the env gene and the 3ЈLTR were removed, we first aimed to generate tat-independent constructs in which all of the 5ЈLTR and most of the leader sequences were removed and replaced by the puissant CMV early promoter/enhancer sequence (in pSIV3+ and all subsequent constructs). We then attempted to remove the vif, vpx and vpr accessory genes (in the pSIV4+ construct), and then the tat regulatory gene (in pSIV5 and following constructs). Finally, in order to eliminate further SIV sequences, we questioned whether the rev/RRE combination could be replaced (in the pSIV6 construct) by a sequence of equivalent functions derived from an avian retrovirus, REV-A, 44 or alternatively, whether the SIV rev gene could be expressed ectopically (in pSIV5, pSIV8 and pSIV10 constructs).
To allow the rigorous comparison of these SIV core expression constructs and in order to evaluate their maximal productivity of infectious viral particles, we first sought to determine their capacity to package the GFPencoding SIV-T1 vector derived from SIVmac251 ( Figure  1b ), rather than a minimal SIVmac251-based vector such as the SIV-RMES4 vector (Figure 1b) . Indeed, while the SIV-T1 vector still contains residual sequences derived from SIV regulatory genes, of which only tat has retained its coding capacity (Table 1 , and unpublished results), the more refined SIV-RMES4 vector is tat dependent and provides significantly lower titers when generated with tatgene negative packaging constructs such as pSIV5 and subsequent plasmids (Table 1) .
All the different SIV gag-pol expression constructs were comparatively evaluated for their capacity to complement in trans the formation of SIV vectors in a transient transfection assay. Thus, highly transfectable 293 human embryo kidney cells were transfected with DNAs of: (1) the tested SIV packaging plasmids (Figure 1a ), (2) the phCMV-G expression vector encoding VSV-G envelope glycoproteins, 45 and (3) the pSIV-T1 packaging-competent GFP-encoding SIV vector (Figure 1b) . A fourth plasmid encoding SIVmac251 rev (pK-Rev) was or was not cotransfected in producer cells to allow expression of SIV core proteins by the pSIV8 packaging construct, that does not express the rev gene, and, additionally, to determine if expression of viral particles by the otherrev-gene expressing -packaging plasmids could be optimized by providing further rev protein expression in the producer cells. For each component of the SIV vector production system, the optimal dose of plasmid DNA, allowing maximal transduction of target cells, was established (data not shown). Transfection efficiencies higher than 90% GFP-positive producer cells were routinely obtained and were, in fact, required to achieve the highest formation of infectious SIV vector particles. Two days after transfection, the supernatants of the transfected cells were harvested and used to infect proliferating sMAGI target cells. The SIV vectors were evaluated by both their transduction efficiencies, determined as percentages of GFP-positive target cells, and their infectious titers, determined by end-point dilutions and followed by FACS analysis of infected cells (Figure 1c) .
With the exception of the pSIV5 and pSIV6 plasmids, all the packaging plasmids were found to allow the efficient formation of SIV vector particles, resulting in the capacity to transduce between 50 and 100% of target cells, as determined 3 days after infection, and in infectious titers of up to 2 × 1O 7 TU/ml ( Figure 1c ). Transduction was inhibited by more than 95% when the target cells were pre-incubated with AZT, a reverse transcriptase inhibitor, thus ruling out passive protein or plasmid DNA transfer (data not shown). Additionally, no differences in the percentages of GFP-positive cells were noticed 2 months versus 3 days after transduction with the SIV vectors (data not shown). Altogether, these results indicated that GFP expression in target cells was achieved by stable transgene delivery, mediated by the lentivirus replication and integration machinery.
Only weak formation of SIV vectors could be obtained with the pSIV6 gag-pol expression plasmid, indicating that the REV-A CTE could not efficiently promote a Rev/RRE-independent expression of SIV genomic mRNAs. Not surprisingly, pSIV8 construct mediated a poor production of SIV vector particles in the absence of rev expression. However, as expected, it was efficiently complemented in trans by the pK-Rev expression plasmid. Additionally, while a significant expression of viral particles was obtained with pSIV5, a strong enhancement of production of SIV vectors was achieved upon its cotransfection with the pK-Rev plasmid, thus indicating that the rev gene carried by the pSIV5 plasmid was not efficiently expressed from the IRES sequence. In contrast to the pSIV5 and pSIV8 constructs, no significant differences in viral production could be noticed using the pSIV3+, pSIV4+ and pSIV10 packaging units, whether the pK-Rev expression plasmid was or was not provided in the producer cells ( Figure 1c ). Altogether, these data indicated that the pSIV3+, the pSIV4+, the pSIV10 and, when combined with the pK-Rev plasmid, the pSIV5 and pSIV8 packaging constructs could efficiently produce SIV viral core particles. The pSIV3+, pSIV4+ and pSIV8 packaging constructs were therefore retained for further analysis.
Gene Therapy
Absence of RCRs in the SIV vector preparations To detect replication-competent retroviruses (RCRs), two assays were designed by using sMagi target cells, permissive to SIVmac251 replication and harboring a stably integrated lacZ transcription unit driven by the SIV/HIV tat-inducible HIV-1 LTR. 46 Simian MAGI cells were primarily infected with VSV-G-pseudotyped SIV vector particles generated by using either the pSIV4+ or the pSIV8 packaging constructs and carrying either the SIV-T1 or the SIV-RMES4 vectors. Infected sMagi cells were checked for both GFP and ␤-galactosidase expression (Table 1) , which respectively indicate SIV vector transduction efficiency and suggest the possible presence of a tat-expressing recombinant retrovirus, and were grown for up to 10 days to allow spreading of an eventual RCR. The capacity of recombinant retroviruses to undergo replication and amplification within this time-frame was controlled using the reverse transcriptase (RT) activity (data not shown) and the tat gene expression (Table 1) in a SIV vector particles were generated with the indicated plasmids and pseudotyped with VSV-G glycoproteins. In parallel, to provide the background values of GFP and ␤-galactosidase expression in primary and secondary target cells, 293 producer cells were transfected with no DNA plasmids (Mock). b sMAGI target cells were infected with 1 ml of the SIV vector preparations, resulting in transduction efficiencies higher than 95% GFP-positive cells and in titers of up to 10 7 TU/ml, except when the SIV-RMES4 vector was propagated using the tat-negative SIV8 packaging construct. In parallel, sMAGI cells were X-gal stained after infection with dilutions of SIV vector preparations. The number of resulting ␤-galactosidase-CFU are indicated for infection with 1 ml of SIV vector supernatants. c One ml of the supernatants of the primary infected cells, passaged for 10 days to allow amplification of an eventual RCR, were used to infect intact sMAGI cells. GFP and ␤-galactosidase expression was checked 3 days after infection. As a positive control for the vector mobilization assay, GFP vector-positive cells (primary cells) were transfected with both pSIV4+ and phCMV-G to provide SIV vector packaging functions. Secondary target cells, infected with the supernatant of these transfected cells, were transduced at an efficiency higher than 75% GFP-positive cells. d Wild-type SIVmac251, grown on macaque PBLs, was used as positive control both for tat gene transduction and expression, as shown by ␤-galactosidase expression in primary infected sMAGI cells, and for RCR amplification. Secondary target cells were infected with 1 ml of the supernatant of the primary infected sMAGI cells, prealably inoculated with 1 l of SIVmac251 and passaged for 10 days. NA, not applicable. sMAGI cells infected by wild-type SIVmac251. The supernatants of the infected primary target cells were then used to infect intact sMAGI cells, as secondary target cells, in order to assess for the putative mobilization of the GFP-containing SIV vector and the potential presence of replication-competent retroviruses ( Table 1) . Detection of both GFP and ␤-galactosidase expression in the secondary target cells remained negative in all experiments performed, thus demonstrating the absence of mobilization of the SIV vector and suggesting that the stocks of SIV vectors were devoid of both RCRs and tat-recombinant retroviruses. Additionally, RT activity remained negative in the supernatants of both primary and secondary infected cells after several passages (data not shown), thus establishing the absence of RCRs in the SIV vector preparations.
Of note, primary target cells infected with SIV-T1 vectors generated by using either pSIV4+ or pSIV8 packaging constructs were found positive for ␤-galactosidase expression (Table 1) . Since the tat gene is absent from the pSIV8 packaging construct, this result indicated that the tat gene had been transduced most probably via the SIV-
Figure 2 Comparisons between SIV-based and HIV-1-based vectors. (a) Titration of lentiviral vectors on 293 (stripped bars) and or sMAGI (black bars) proliferating cells, as TU/ml. SIV and HIV-1 vectors were generated with VSV-G envelope glycoproteins, with the indicated GFP-encoding lentiviral vectors, and with the viral packaging functions encoded by the indicated plasmids. (b) Titration of cross-packaged lentiviral vectors on 293 proliferating cells, as TU/ml. SIV and HIV-1 vectors were generated with the indicated GFP-encoding lentiviral vectors, with VSV-G envelope glycoproteins and with plasmids encoding SIV and HIV-1 core proteins: pSIV3+ and pCMV⌬8.2 plasmids (black bars) or pSIV4+ and pCMV⌬8.91 plasmids (stripped bars), expressing, or not, the vif, vpx (for SIV), vpr, and vpu (for HIV-1) accessory proteins, respectively.
T1 vector (Figure 1b) itself rather than via a parasite packaging/transduction of the pSIV4+ helper genome, or, more unlikely, via an unexpected recombinant retrovirus. To ascertain this point, similar experiments were performed by using the SIV-RMES4 minimal vector (Figure 1b) , which does not contain any SIV gene. Although SIV vectors generated using the SIV-RMES4 vector and the pSIV4+ gag-pol construct could efficiently transduce the GFP marker into primary target cells, neither lacZ gene expression in primary target cells nor GFP or ␤-galactosidase in secondary infected cells could be detected (Table 1) . Identical results were obtained when the SIV-RMES4 vector was propagated using the pSIV8 packaging construct although at lower titers ( 
Comparison between HIV-1-and SIV-derived vectors
The pSIV3+ and pSIV4+ viral core expression backbones are equivalent in structure to the pCMV⌬R8.2 and pCMV⌬R8.91 packaging plasmids, which express HIV-1 gag and pol proteins, with or without lentiviral accessory proteins, respectively. 41 These four SIV-or HIV-1-derived packaging constructs were comparatively evaluated in side-to-side experiments for their capacity to generate SIV-based-or HIV-1-based vectors. In these experiments, either the SIV-T1 and SIV-RMES4 SIV-based vectors or the HRЈCMV-GFP HIV-1-based vector, 35 all carrying CMV promoter-driven GFP-expression cassettes, were used to transduce 293 human target cells as well as sMAGI simian target cells (Figure 2a) . The SIV-T1 vector was more efficient than the SIV-RMES4 minimal vector and gave rise to approximately 10-fold higher titers. Titers of the HRЈCMV-GFP HIV-1-based vector, of approximately 6 × 10 6 TU/ml, were intermediate between those of the SIV-T1 and SIV-RMES4 SIV vectors on 293 target cells. However, a significant discrepancy between SIVderived and HIV-1-based vectors was found when sMAGI simian versus 293 human target cells were compared in the titration assays. In comparison with the HRЈCMV-GFP HIV-1-vectors, titers of the SIV-T1 and SIV-RMES4 SIV-vectors were five-to 20-fold better on the simian target cells than on the human target cells, and vice versa (Figure 2a) , most probably reflecting the adaptation of either lentiviruses with cells derived from their natural hosts.
We next attempted to cross-package SIV-based or HIV-1-based vectors with core particles derived from HIV-1 or SIV, respectively (Figure 2b ). HIV-1 core particles could efficiently cross-package the SIV-T1 and SIV-RMES4 SIVderived vectors and allowed transduction of target cells with an efficiency decreased by four-fold, at most, comparatively to that of the same SIV-based vectors packaged with homologous SIV core particles. In contrast, the infectious titers of the HRЈCMV-GFP HIV-1-based vector were strongly reduced, by up to 1000-fold, when they were generated with SIV core particles (Figure 2b) . These results were consistent with other studies addressing the capacity of the SIV genome to be packaged in HIV-1 viral particles 47 and the nonreciprocal packaging of HIV-2 genome, which is closely related to that of SIV, into HIV-1 core particles. 48 Since previous studies have shown that the reduction of sequence homology between vector and packaging components is an important parameter in decreasing the risk of the emergence of recombinant retroviruses, 1 that SIV-based vectors can be efficiently generated with HIV-1 core particles may therefore provide an additional safety feature to lentiviral vectors.
Pseudotyping of SIV vectors SIV vectors characterized here so far have been generated as VSV-G-coated retroviral particles. Since the transduction efficiency of target cells is dependent on the type of glycoprotein used to coat retroviral vectors, [49] [50] we next determined the infectivity of SIV vector particles generated with envelope glycoproteins derived from 10A1-MLV (murine leukemia virus), GALV (gibbon ape leukemia virus) and with an influenza virus H7-HA Gene Therapy hemagglutinin. To minimize variations in expression, all four glycoproteins types were produced using an expression backbone identical to that used in previous experiments for VSV-G-pseudotype formation. Significant differences were found in the capacity of these various glycoproteins to pseudotype SIV-vector particles, although all SIV pseudotypes were found to allow transduction of 293 target cells (Figure 3a) and of other human cell types (data not shown). In comparison with VSV-Gcoated particles, HA-pseudotyped SIV vectors were about 200-fold less infectious, with titers of up to 2.5 × 10 4 TU/ml on 293 target cells. SIV vectors pseudotyped with 10A1-MLV and GALV envelope glycoproteins had similar titers (between 1.3 × 10 5 and 2 × 10 5 TU/ml), but were respectively 20-and 30-fold less infectious on 293 target cells than SIV particles coated with VSV-G glycoproteins (Figure 3a) . In contrast, when the same glycoproteins were used to coat MLV retroviral vectors, much weaker variations were found in the infectious titers of the different MLV pseudotypes (Figure 3b ). These data indicated that VSV-G was the best glycoprotein for preparing pseudotypes of SIV vectors, although the other types of glycoproteins might be valuable for transduction of specific target cell types in vivo. Indeed, while the transduction efficiency of the VSV-G pseudotypes was higher than 95%, thanks to their high titers allowing the use of high MOIs (more than 10 infectious particles per cell), up to 67% and 43% of GFP-positive cells could be obtained with the 101A-MLV and GALV SIV-vector pseudotypes, respectively, using much lower MOIs, of less than one infectious particle per cell (Figure 3 ).
Transduction of human dendritic cells
The SIV vectors were then evaluated for their ability to transduce nonproliferative human dendritic cells (DCs), obtained by IL4/GM-CSF-mediated differentiation of blood monocytes. DCs, as assessed by immunostaining using monoclonal antibodies against CD1a, CD80, CD86 and MHC class II molecules (Figure 4a ), were transduced by using the SIV-T1 vector and either the pSIV3+ or
Figure 3 Infectivity of SIV-and MLV-vector pseudotypes. (a) SIV vectors were generated with the SIV-T1 GFP-encoding vector, the pSIV4+ packaging plasmid and the indicated glycoproteins. Titers determined on 293 target cells, as TU/ml. (b) MLV vectors were generated with the indicated glycoproteins. Titers determined on 293 target cells, as TU/ml. On the top of the bars, the transduction efficiencies obtained after infection of 2.5 × 10
5 target cells using 1 ml of vector supernatant are shown.
Figure 4 Transduction of human dendritic cells. (a) Immunophenotyping of monocyte-derived DCs. The proportion of viable cells positive for expression of the indicated cell surface antigens is shown. The histograms of cells stained with control isotype-matched antibodies are shown as dotted lines. (b) Results of transduction of proliferating 293 cells or nonproliferating immature or mature human dendritic cells (DCs), using VSV-G pseudotypes of GFP-encoding MLV-vectors (empty bars) or SIV-T1 SIV-vectors generated with the pSIV3+ or the pSIV4+ packaging constructs, expressing (grey bars), or not (stripped bars), the vif, vpx and vpr accessory proteins, respectively. Target cells were transduced using an MOI of one infectious viral particle per cells, as determined by titration assays on proliferating 293 target cells, using end-point dilutions of the vector stocks. Mock, infection of target cells using supernatants of producer cells transfected without any plasmid. (c) Immunophenotyping of GFP-transduced mature DCs. SIV vectortransduced cells (lower dot-plot) or mock-transduced cells (upper dot-plot), grown in the presence of CD40 ligand after infection, were stained with PEconjugated Mab against MHC class II molecules and analyzed for both MHC class II (indicative of mature DCs) and GFP expression. (d) Optimization of a gene transfer protocol into human DCs. Immature DCs were transduced with either the SIV-T1 vector or the SIV-RMES4 minimal vector, both generated using the pSIV3+ packaging plasmid, and, as control, an MLV vector. MOIs of 10 infectious particles per target cell were applied. SIV vectorinfected cells were or were not maturated by co-cultivation with human CD40L-expressing mouse fibroblasts for 3 and 5 days before determining the transduction efficacy. GFP transduction in the mature DCs was inhibited by up to 80% when infection was carried out in the presence of 10 m AZT (data not shown).
pSIV4+ packaging constructs which express, or not express, most of the SIV accessory genes (except nef), respectively. Retroviral vectors derived from MLV (murine leukemia virus) were used as control. Both lentiviral and retroviral vectors, generated as VSV-G-pseudotyped particles, had similar titers on proliferating cells (around 5 × 10 6 TU/ml) and were used to infect human DCs with a low MOI, of one infectious particle per target cell (Figure 4b ). Infected immature DCs were then co-cultured either with irradiated mouse fibroblasts expressing the human CD40 ligand, to allow their differentiation into mature DCs, 51 or with irradiated mouse fibroblasts expressing the human CD32, as control. GFP expression was measured 3 days after transduction and the mature DC phenotype of the GFP-positive cells was ascertained by immunostaining of MHC class II molecules and FACS analysis (Figure 4b and c) . No GFP-positive cells were found in DCs infected with MLV-based vectors ( Figure  4b ), owing to the incapacity of the latter type of vectors to integrate into non proliferating cells. 13 In contrast, using the same MOIs, the preparations of SIV-based vectors could transduce the human DCs, although with variable efficiencies (Figure 4b ). While immature DCs could be transduced with an efficiency of up to 8.5% GFP-positive cells, GFP expression was detected in up to 18% of the mature DCs, most probably owing to the increased metabolism of these activated cells. Treatment of the target cells with AZT during and after infection was found to prevent GFP transduction by more than 90% when monitored 3 days after transduction (data not shown), thus ruling out the possibility that GFP expression detected in cells transduced in the absence of AZT was due to pseudo-transduction or phagocytosis of plasmid DNA (data not shown). Maturation of DCs, a pre-requisite in fulfilling their role of antigen-presenting cells and activation of the immune system, is characterized by up-regulation of MHC class II molecules. Since the same proportion of cells with high MHC class II expression -approximately 90% -was detected in both the nontransduced DCs and the GFP-transduced DCs (Figure 4c ), our results indicated that SIV vectormediated gene transfer did not impair the maturation and properties of DCs. In comparison with SIV vectors generated with pSIV4+ helper plasmid, SIV vectors generated with the pSIV3+ packaging construct could transduce the DCs better (Figure 4b ). Since no differences were found between the two SIV vector preparations for infection of proliferating cells, the reproducible enhancement of transduction of DCs by SIV vectors generated with the pSIV3+ packaging construct probably resulted from the expression of accessory proteins, such as vpx/vpr, which have been found to facilitate nuclear import of the lentiviral preintegration complex in some terminally differentiated cell types. 22, 52 To improve gene transfer and expression into DCs, we sought to increase both the MOI and the duration of DC maturation with the CD40 ligand. Using the optimal conditions of 10 infectious particles per cell and 5 days of co-cultivation of the transduced DCs with CD40L-expressing mouse fibroblasts, transduction efficiencies of up to 33% GFP-positive cells could be obtained ( Figure  4d ). In addition, at the same MOIs, no significant difference in transduction efficiency was found when the SIV-T1 vector was compared with the minimal SIV-RMES4 vector for infection of DCs (Figure 4d) .
Altogether, these results indicated that SIV vectors could efficiently transduce nonproliferating primary human dendritic cells. Efficient gene transfer could be obtained by using a minimal SIV vector and transduced DCs were found to retain their biological properties, such as MHC class II molecule up-regulation in response to CD40L-induced maturation. Moreover, in addition to providing an optimized protocol for ex vivo transduction of human DCs, we also report here that our SIV vectors could achieve an efficient gene transfer at a low MOI, a critical requirement for approaching in vivo gene delivery.
Discussion
We report here the generation of novel lentivirus vectors, derived from SIVmac251. Our vectors could efficiently transduce nonproliferating cells, as established using terminally differentiated human dendritic cells and sideto-side comparisons with HIV-1-based vectors. In a manner similar to vectors derived from other types of lentiviruses, SIV-derived vectors were produced in 293 cells by transient expression after transfection of plasmid DNAs encoding the different components required for assembly of SIV vector particles. Although widely used for producing lentivirus vectors, the use of such methods might prove difficult to scale-up vector production and to pass quality control and validation processes, due to the various types of contaminants that may be found in vector stocks obtained by transient expression. Stable packaging cell lines have been produced for HIV-1-based vectors, yet they were found to release low titers of infectious particles, [53] [54] [55] owing to the properties of proteins encoded by some lentiviral genes which may exert a negative effect on the viability of the producer cells. Alternative systems for producing lentivirus vectors have been obtained by generating packaging cell lines whose expression can be induced. 37, 42, 56 Although these inducible packaging cell lines seem to be less efficient Gene Therapy than the transient production method, they represent an important step toward the large-scale production of lentiviral vectors for clinical application. Of note, we have recently described hybrid vectors derived from powerful viral vectors, such as herpes virus amplicons or recombinant adenoviruses, which were engineered to induce the safe formation of high titer MLV-based vectors. 57, 58 We are currently investigating the properties of lentiviral vectors generated by using such hybrid vectors.
Among the important issues raised by the utilization of viral vectors in gene therapy is the absence of replicationcompetent viruses, especially when the former are derived from pathogenic viruses such as primate lentiviruses. In practice for lentiviral vectors, both the removal of the env, tat, and accessory genes and the repartition of the transfer and packaging functions on separate units with minimal sequence overlaps seems to satisfy biosafety criteria and to prevent the emergence of replication-competent retroviruses, as demonstrated here for the SIV-based vectors (Table 1) . Furthermore, the obtention of self-inactivating vectors either for HIV-1-derived vectors 59, 60 or for our SIV-based vectors 65 should add an additional safety level, by preventing vector mobilization upon infection with an exogenous lentivirus, 61 for example. Moreover, our results show that either HIV-1-based or SIV-derived vectors can be cross-packaged in core particles of the converse lentivirus, although only the propagation of SIV vectors into HIV-1 core particles gave rise to high infectious titers (Figure 2b) . The low nucleotide sequence homology between HIV-1 and SIVmac251, about 33% for their non-coding regions, should therefore further reduce the likelihood of recombination for such hybrid SIV/HIV-1 vector systems.
Despite all the biosafety safeguards that have progressively been added, the use of lentiviral vectors derived from pathogenic primate lentiviruses raises serious concerns on their clinical acceptance. At present, it is not clear which type of lentivirus vector, derived from either primate or nonprimate lentiviruses, should be better accepted. The biosafety of either vector type should be proven in vivo in animal models for HIV-induced disease before their use in humans. However, since HIV-1 causes AIDS only in humans, there is no suitable animal model in which the safety of HIV vectors could be evaluated, thus providing a serious limitation for the pre-clinical testing of HIV-based vectors. Since SIVmac251 is a causative agent of simian AIDS, the biosafety of lentiviral vectors may therefore be tested in a monkey model. Thus the SIV vectors may provide a valid alternative to HIV-1-based vectors, at least in the early phases of the clinical testing of lentivirus vectors.
Lentiviral vectors are promising tools for in vivo gene delivery since, unlike MLV-based vectors, they may stably transduce quiescent cells in various organs. 25, [35] [36] [37] [38] [39] To be of real benefit for in vivo administration protocols, such vectors should be infectious at low MOIs, since only MOIs of far less than one would be applicable in vivo. Here, we have shown that SIV-based vectors could efficiently transduce nonproliferating monocyte-derived mature human DCs, at an MOI of one infectious particle per target cell, thus establishing the value of these novel lentiviral vectors. Moreover, GFP-transduced DCs could be differentiated in vitro into mature DCs, suggesting that they had retained their biological properties. We are currently investigating whether DCs transduced in vitro with various antigen-encoding SIV vectors can activate cytotoxic T cells and lead to effective CTL vaccines. We also describe here a protocol that allows efficient gene transfer into monocyte-derived human DCs, resulting in transduction of up to 33% target cells.
Additionally, we show here that SIV vectors can be efficiently pseudotyped with surface glycoproteins derived from a wide range of membrane-enveloped viruses, VSV, MLV, GALV and influenza virus. This finding opens the way to transducing cell types that may be refractory to infection with VSV-G pseudotypes. Besides, VSV-G-coated vector particles may not be suitable for an in vivo gene delivery by systemic administration, since, due to the wide distribution of its receptor -a lipid component of the plasma membranethey may stick on the surface of all cells encountered after inoculation before they have the chance of reaching the gene therapy target cells. Additionally, since MLV envelope glycoproteins and influenza virus hemagglutinin could efficiently pseudotype the SIV vectors (Figure 3a) , it will be possible to exploit the wide range of receptortargeted glycoproteins that have been engineered using these two proteins types, 8 in order to modify the host range of lentivirus vectors.
Materials and methods

Construction of SIV gag/pol expression plasmids
The BK28 molecular clone of SIVmac251 40 was used to derive the SIV packaging constructs. The nucleotide sequence of SIVmac251 has the GenBank accession number M19499. Starting from the SIVmac251 provirus (a kind gift of Jim Mullins, Department of Microbiology, University of Washington, Seattle, WA, USA), a methodical approach was used to engineer both efficient and safe expression plasmids allowing the production of SIV viral core proteins (Figure 1a ). In the pSIV2 packaging plasmid, the U3 region of the 5Ј LTR of SIVmac251 (nts 1 to 506) was replaced by the human cytomegalovirus earlyimmediate promoter and enhancer region (CMV promoter). In addition, the 5Ј half of the env gene (nts 6582 to 7981) was removed, leaving intact the RRE (Revresponsive element) sequence as well as the 5Ј and 3Ј exons of the tat and rev regulatory genes. Furthermore, the 3Ј LTR (nts 9444 to 10249) was replaced by an SV40 polyadenylation sequence, thus resulting in deletion of the 3Ј end of the nef gene. Finally, the initiation codon of nef was inactivated to prevent translation. pSIV3+ was generated by removing from the pSIV2 construct a sequence (nts 507 to 959) encompassing R, U5 and the 5Ј half of the leader region (up to the major splice donor site (MSD), nts 967 to 980). In pSIV4+, a construct similar in structure to pSIV3+, the genes encoding the vif, vpx and vpr SIV accessory proteins were inactivated by partial deletion (from nts 5388 to 6249) and inactivation of the vif gene initiation codon. Further CMV promoterdriven SIV packaging constructs were generated by PCR to remove most of the residual sequences of the accessory genes. First, the 5Ј part of the pSIV4+ construct (from the CMV promoter to the end of the pol gene -nt 5396) was fused to the SIV RRE sequence (nts 8021 to 8527), thus resulting in the pSIV8 expression construct. Second, a cassette encompassing the sequence of EMCV (encephalo-myocarditis virus) IRES (internal ribosomal entry site) and a SIV rev cDNA, in which the two rev gene exons (nts 6504 to 6573 and nts 8785 to 9041) were fused, was inserted after the SIV RRE sequence of pSIV8, thus resulting in the pSIV5 expression plasmid. In pSIV6, derived from pSIV8, the SIV RRE sequence was replaced by the REV-A (reticuloendotheliosis virus type A) R-U5-leader region which may contain a constitutive transport element (CTE), as suggested by a recent study on SNV (spleen necrosis virus), an avian retrovirus that shares extensive sequence homology with REV-A. 44 To express the rev gene from a transcription unit different from that of the gag-pol genes, the SIVmac251 rev cDNA was inserted into the pSI mammalian expression plasmid (Promega, Charbonnières, France) and placed under control of the SV40 early promoter, chimeric ␤-globin gene intron and SV40 polyadenylation sequences, resulting in the pK-Rev plasmid. The SV40-driven expression unit of the rev gene was excised from pK-Rev and inserted downstream into the polyadenylation sequence of pSIV8, thus resulting in the pSIV10 packaging plasmid.
Other plasmids
The pSIV-T1 and pSIV-RMES4 (Figure 1b) are packagingcompetent SIVmac251-based vectors. 65 Both SIV vectors contain the enhanced green fluorescent protein (GFP) marker gene under control of the CMV promoter placed between the SIVmac251 LTRs and leader sequences, and carry the SIVmac251 rev-responsive element (RRE) and minimal sequences of the gag and pol genes (the first 218 or 57 nts of the gag gene and the last 1007 nts or a 141 bps pol gene-derived fragment encompassing the cPPT/CTS regions (nts 5048 to 5189), for the pSIV-T1 or the pSIV-RMES4 vectors, respectively). While the pSIV-T1 vector still contains residual sequences derived from some of the SIVmac251 accessory genes (Figure 1b) , of which only the tat gene has retained its coding capacity, pSIV-RMES4 is a minimal vector and retains less than 15% nucleotides derived from the parental SIVmac251 RNA genome. 65 The pCMV⌬8.2 25 or pCMV⌬8.91 41 HIV-1 packaging plasmids and the pHRЈCMV-GFP HIV-1-based vector 35 were described elsewhere and were kindly provided by Didier Trono (Department of Genetics and Microbiology, University of Geneva, Switzerland).
The pTG5349 murine leukemia virus (MLV) packaging plasmid and the pTG13077 plasmid, encoding an MLVbased vector containing a CMV-GFP internal transcriptional unit, were kindly provided by Transgene (Strasbourg, France).
The following plasmids, phCMV-G, 45 phCMV-HA, 62 phCMV-10A1 63 and phCMV-GALV (S Chapel-Fernandes and F-LC, unpublished material) are envelope-expression constructs that respectively encode the vesicular stomatitis virus (VSV) G protein, an influenza virus H7-HA hemagglutinin, the 10A1-MLV and the gibbon ape leukemia virus (GALV) envelope glycoproteins, all under control of the CMV promoter, rabbit ␤-globin intron II and polyadenylation sequences.
Cells
The 293 human embryo kidney cell line (ATCC CRL-1573) and the CD4-positive sMAGI macaque cell line, 46 which expresses a lacZ gene under control of the SIV/HIV-tat-responsive HIV-1 LTR, were grown in DMEM (Life Technologies, Cergy Pontoise, France) supplemented with 10% fetal bovine serum (FCS).
Human dendritic cells (DCs) were prepared from blood monocytes from Ficoll/Percoll-purified human peripheral blood mononuclear cells after immunodepletion of T and B lymphocytes and NK cells, as previously described. 64 After 6 days of culture in the presence of 50 ng/ml hrGM-CSF and 500 U/ml hrIL-4 (kindly provided by the Schering-Plough Laboratory for Immunological Research, Dardilly, France), more than 95% of the cells were DCs as assessed by CD1a labeling. Cultures of the DCs were performed in 24-well flat-bottomed microtiter plates (Falcon/Becton Dickinson, Le Pont de Claix, France), in a total volume of 1 ml, in RPMI 1640 (Life Technologies) supplemented with 10 mm Hepes (Life Technologies), 2 mm l-glutamine (Life Tech-nologies), 40 g/ml gentamicin (Life Technologies), and 10% FCS (Boehringer Mannheim, Meylan, France). For immunophenotyping, DCs or GFP vector-transduced DCs were washed in ice-cold phosphate buffer saline (PBS) supplemented with 1% bovine serum albumin (BSA) and 3% human serum in PBS. DCs were stained using 2 g/ml phycoerythrin (PE)-conjugated monoclonal antibodies (mAb) specific for CD1a (BL6; DAKO, Glostrup, Denmark), CD80 (L307.4; Becton Dickinson Immunocytochemistry Systems, San Jose, CA, USA), CD86 (BU63; Serotec Ltd, Oxford, UK) and MHC class II molecules (L243; Becton Dickinson Immunocytochemistry Systems). DCs were also stained with corresponding isotype-matched control mAb (Immunotech, Marseilles, France). Surface expression was analyzed using a FACSCalibur flow cytometer (Becton Dickinson, Pont-de-Claix, France). Viable DCs were gated according to negative staining with propidium iodide. Data were collected from 5000 to 10 000 viable cells and analyzed using CellQuest software (Becton Dickinson Immunocytochemistry Systems).
Production of lentiviral and retroviral vectors
The VSV-G-pseudotyped HIV-1-derived vectors were generated as previously described 25 by transient transfection in 293 cells of the pHRЈCMV-GFP vector construct (8.1 g) with the VSV-G-expressing construct phCMV-G (2.7 g) and either the pCMV⌬8.2 or pCMV⌬8.91 packaging constructs (8.1 g). MLV-derived vectors pseudotyped with VSV-G or other viral surface glycoproteins were generated in a similar manner by transient transfection of the pTG5349 MLV packaging construct (13.2 g) with pTG13077 MLV vector construct (13.2 g) and the envelope-expressing construct (3.1 g). SIV-derived vectors were generated by transfecting the SIV packaging constructs (8.1 g) with either the pSIV-T1 or the pSIV-RMES4 vector constructs (8.1 g) and the envelope-expressing construct (2.7 g) in the presence of 10.8 g of either a carrier DNA (pUC19) or the pK-Rev expression plasmid.
Plasmid DNAs were transfected into 2.4 × 10 6 293 cells seeded the day before in 10-cm plates using the calciumphosphate transfection system (Life Technologies, France) according to the manufacturer's recommendations. The medium (12 ml per plate) was replaced 15 h after transfection, and supernatant was harvested 36 h after the start of the transfection, filtered through 0.45-m pore-sized membranes, and stored at −80°C.
Transduction assays
To determine the transduction efficiency and infectious titer, 293 or sMAGI target cells were seeded at a density Gene Therapy of 2.5 × 10 5 per well in six-well plates 1 day before transduction. Serial dilutions of vector preparations were added to the cells in the presence of 6 g of polybrene/ml, and the cultures were incubated for 4 h at 37°C. The vector-containing medium was then replaced with normal culture medium and the cells were incubated for 72 h at 37°C. The percentage of GFP-positive cells was determined by FACS analysis, following individualization of the transduced cells in trypsine and fixing of the cells in 4% formaldehyde in PBS. The transduction efficiency was arbitrarily determined as the percentage of GFP-positive cells after transduction of 2.5 × 10 5 target cells with 1 ml of viral supernatant. The infectious titers, provided as transducing units (TU)/ml, were calculated by using the formula: Titer = %inf × (2.5 × 10 5 /100) × d, where d is the dilution factor of the viral supernatant and %inf is the percentage of GFP-positive cells as determined by FACS analysis using dilutions of the viral supernatant that transduce between 5% and 10% of GFP-positive cells. ␤-Galactosidase expression in vector-transduced sMAGI cells was assayed 72 h after infection. Cells were fixed and stained with X-gal (5-bromo-4-chloro-3-indolyl-␤-d-galactopyranoside) as previously described.
1 ␤-Galactosidase-positive colonies were counted and the infectious titers of the tat-expressing retroviruses were expressed as CFU/ml.
To infect the human DCs, 1 ml of diluted viral supernatants containing 10 5 TU of infectious particles, as determined beforehand on 293 target cells, was added to 10 5 DCs suspended in 0.1 ml of DC medium. DCs were infected in the presence of 6 g of polybrene/ml for 4 h at 37°C, then washed and incubated for 48 h in normal DC medium in the presence of 2 × 10 4 irradiated (7000 rads) fibroblastic CD40 ligand-or CD32-transfected L mouse cells (both kindly provided by Schering-Plough Laboratory for Immunological Research) to allow, or not allow, differentiation into mature DCs, respectively. 51 To rule out pseudo-transduction by free GFP or by GFP-containing pseudo-particles or by DNA plasmids released by the producer cells and ingested by the DCs, experiments were performed in duplicate in the absence or the presence of 10 m AZT (3Ј-azido-3Ј-deoxythymidine; SigmaAldrich, Saint Quentin Fallavier, France), an inhibitor of reverse transcriptase, which was added 60 min before infection until transduction analysis. Transduction efficiency was then assessed by FACS analysis 2 and 5 days after infection.
